Syeda Kit
Product Images NDC 63629-2335

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Syeda (NDC 63629-2335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 01)

FDA Label Image

Figure 2 (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 02)

This text provides a figure showing the likelihood of developing a VTE (venous thromboembolism) among non-pregnant women who are not taking COC (combination oral contraceptives), non-pregnant COC users, pregnant women (based on actual pregnancy duration), and postpartum women (only up to 12 weeks). The figure also shows the number of women with blood clots per 10,000 women years (WY).*

FDA Label Image

Structure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 03)

Drospirenone Ethinyl estradiol is a combination medication used as a form of birth control.*

FDA Label Image

Figure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 04)

This text provides information on different types of birth control methods and their effectiveness rates based on the number of pregnancies per 100 women in one year. The methods listed include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, no sex during the most fertile days of the monthly cycle, spermicide, withdrawal, and no birth control. The effectiveness rates vary from fewer than 1 pregnancy per 100 women in one year to 85 or more pregnancies per 100 women in one year.*

FDA Label Image

Figure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 06)

This is a chart presenting the likelihood of developing a serious blood clot. The data is broken down into four categories: non-pregnant non-COC users, non-pregnant COC users, pregnant and postpartum (12 weeks only). The chart shows that the likelihood of developing a blood clot is higher for those who use COC and those who are pregnant or postpartum. The data is measured in numbers of women with a blood clot out of 10,000 women years (WY). The pregnancy data is based on actual duration of pregnancy in the reference studies and ranges from seven to 27 per 10,000 WY.*

FDA Label Image

Label (Lbl636292335)

This is a description of a medication named Drospirenone and Ethinyl Estradiol Tablets, containing 3 mg of Drospirenone and 0.03 mg of Ethinyl Estradiol. The medication comes in blister cards, with each card containing three units, each of which contains one 28-tablet blister pack. The 21 yellow tablets contain the medication, while the 7 white tablets are inert. The package is not child-resistant, and should be kept out of reach of children. The medication should be stored at a temperature between 20°C and 25°C. The NDC number is 63629-2335-1.*

FDA Label Image

Syeda (Syeda)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.